KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Average (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Equity Average data on record, last reported at $31.1 billion in Q4 2025.

  • For Q4 2025, Equity Average rose 6.02% year-over-year to $31.1 billion; the TTM value through Dec 2025 reached $31.1 billion, up 6.02%, while the annual FY2025 figure was $30.3 billion, 9.55% up from the prior year.
  • Equity Average reached $31.1 billion in Q4 2025 per REGN's latest filing, up from $30.4 billion in the prior quarter.
  • Across five years, Equity Average topped out at $31.1 billion in Q4 2025 and bottomed at $11.5 billion in Q1 2021.
  • Average Equity Average over 5 years is $25.0 billion, with a median of $26.5 billion recorded in 2024.
  • Peak YoY movement for Equity Average: decreased 0.95% in 2021, then surged 49.8% in 2022.
  • A 5-year view of Equity Average shows it stood at $13.6 billion in 2021, then surged by 49.8% to $20.3 billion in 2022, then increased by 25.31% to $25.4 billion in 2023, then increased by 15.33% to $29.3 billion in 2024, then grew by 6.02% to $31.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $31.1 billion in Q4 2025, $30.4 billion in Q3 2025, and $29.7 billion in Q2 2025.